Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
At Creative Biolabs, we offer various anti-FCRL1 CAR products that are designed to target FCRL1-expressing malignancies with high specificity and efficacy. Our comprehensive range of anti-FCRL1 CAR products includes CAR vectors, CAR mRNA, and CAR cells, all aimed at providing innovative immune cell therapies for the treatment of FCRL1-associated diseases.
Fc receptor-like 1 (FCRL1) is a cell surface protein that belongs to the immunoglobulin superfamily. It is a member of the Fc receptor-like family of proteins, which are involved in the regulation of immune responses. FCRL1 is primarily expressed on the surface of B cells and subsets of T cells, and plays a role in modulating immune signaling pathways. It has been suggested that FCRL1 may function as an inhibitory receptor, modulating the activity of other immune receptors and dampening immune responses. FCRL1 has been implicated in various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, as well as in certain types of cancer. By targeting FCRL1, researchers hope to regulate aberrant immune responses and potentially improve outcomes for patients with autoimmune diseases or cancer.
Fig.1 Schematic of the FCRL family of proteins.1
Associated Disease
Creative Biolabs offers comprehensive in vitro assays to assess the efficacy and safety of anti-FCRL1 CAR-T cell therapy, including:
We provide several anti-FCRL1 CAR-T expression tests including WB, FCM, and RT-PCR. These tests are designed to analyze different aspects of the expression and functionality of FCRL1-targeting CAR-T cells
The CAR-T proliferation test specifically focuses on measuring the proliferation capacity of CAR-T cells, which refers to their ability to grow and expand in response to a specific antigen target. Our experts utilize various assays and techniques to assess the rate of cell growth and expansion of CAR-T cells in response to the targeted antigen stimulation
At our labs, our cytokine release tests typically measure the levels of various cytokines, such as interferon-gamma, interleukin-2, interleukin-6, and tumor necrosis factor-alpha, in the supernatant of cell cultures containing the CAR T cells and target cancer cells. Elevated levels of cytokines in this test can indicate that the CAR T cells are actively recognizing and attacking the cancer cells.
In vitro CAR-T cell cytotoxicity assays are valuable tools for evaluating the killing potential of CAR-T cells and optimizing their therapeutic efficacy for the treatment of cancer and other diseases. Our team offers several types of in vitro cytotoxicity assays that can be used depending on the specific research question and the type of cells being studied, including imaging-based assays, chromium release assay, and LDH release assay.
CAR-T in vivo assays are tests used to evaluate the effectiveness of CAR-T cell therapies in living organisms, typically in animal models like mice. We provide various assays that involve injecting the CAR-T cells into the animal models and monitoring their ability to target and kill cancer cells or other target cells expressing the specific antigen.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-1122-YF5933 | Anti-FCRL1 (XW-413) h(CD28-CD3ζ) CAR, pAAV | Human | XW-413 | Human | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5934 | Anti-FCRL1 (XW-414) h(CD28-CD3ζ) CAR, pAAV | Human | XW-414 | Human | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5935 | Anti-FCRL1 (XW-415) h(CD28-CD3ζ) CAR, pAAV | Human | XW-415 | Human | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF5936 | Anti-FCRL1 (XW-416) h(CD28-CD3ζ) CAR, pAAV | Mouse | XW-416 | Rat | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF6853 | Anti-FCRL1 (XW-413) h(41BB-CD3ζ) CAR, pAAV | Human | XW-413 | Human | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF6854 | Anti-FCRL1 (XW-414) h(41BB-CD3ζ) CAR, pAAV | Human | XW-414 | Human | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF6855 | Anti-FCRL1 (XW-415) h(41BB-CD3ζ) CAR, pAAV | Human | XW-415 | Human | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF6856 | Anti-FCRL1 (XW-416) h(41BB-CD3ζ) CAR, pAAV | Mouse | XW-416 | Rat | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF7773 | Anti-FCRL1 (XW-413) h(CD28-41BB-CD3ζ) CAR, pAAV | Human | XW-413 | Human | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF7774 | Anti-FCRL1 (XW-414) h(CD28-41BB-CD3ζ) CAR, pAAV | Human | XW-414 | Human | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF7775 | Anti-FCRL1 (XW-415) h(CD28-41BB-CD3ζ) CAR, pAAV | Human | XW-415 | Human | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-YF7776 | Anti-FCRL1 (XW-416) h(CD28-41BB-CD3ζ) CAR, pAAV | Mouse | XW-416 | Rat | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-0123-ZP383 | Anti-FCRL1 (2G5) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 2G5 | Human | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP384 | Anti-FCRL1 (7G8) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 7G8 | Human | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP385 | Anti-FCRL1 (5A2) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 5A2 | Human | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP592 | Anti-FCRL1 (CB-P76) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | CB-P76 | Rat | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP383 | Anti-FCRL1 (2G5 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 2G5 | Human | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP384 | Anti-FCRL1 (7G8 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 7G8 | Human | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP385 | Anti-FCRL1 (5A2 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 5A2 | Human | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP592 | Anti-FCRL1 (CB-P76 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | CB-P76 | Rat | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
